Efficacy and Safety of 500mg of Fulvestrant

Exclusion Criteria

• •Presence of life-threatening metastatic disease
• •Endocrine therapy the advanced disease setting
• •Systemic chemotherapy, whether as adjuvant therapy or for advanced disease, within previous 4 weeks
• •Trastuzumab or biologic therapy within previous 2 weeks
• •Extensive radiation therapy within the last 2 weeks
• •Prior adjuvant or neoadjuvant treatment with fulvestrant is not allowed
• •Concomitant anticancer treatments
• •Chronic bisphosphonates for hypercalcemia or prevention of bone metastases
• •Subjects receiving long-term anticoagulant therapy with warfarin
• •Estrogen replacement therapy within 6 months of trial entry
• •Previous or current systems malignancy within the past 3 years
• •Treatment with non approved or investigational drug within 2 weeks before study entry
• •Any evidence of severe or uncontrolled systemic disease
• •History of bleeding diathesis
• •Any severe concomitant condition which makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the study protocol